Literature DB >> 12764628

T-cell-mediated mucosal immunity is attenuated in experimental necrotizing enterocolitis.

A Anttila1, H Kauppinen, A Koivusalo, P Heikkila, E Savilahti, R Rintala.   

Abstract

In premature infants with necrotizing enterocolitis (NEC) the gastrointestinal mucosal barrier is immature, but little is known about the immune response of immature bowel. The aim of this study was to evaluate the intestinal mucosal immune response in experimental NEC. In general anaesthesia, NEC was induced in six newborn piglets by injection of bovine casein into terminal ileum. Six controls received an equal amount of saline. Four hours later, samples were taken from the macroscopically most affected part of the treated loop and from the macroscopically healthy untreated intestine. Monoclonal antibodies to porcine CD1, CD2, CD4, CD8, CD45 and IgM were used for immunohistochemical staining. Casein-treated bowel showed typical macro- and microscopic findings of NEC. No changes were found in the saline-treated bowel. In both groups the bowel outside the treatment sector was normal. In casein-treated animals, treated samples showed significant decrease in density of CD4+ cells when compared with saline-treated controls. Similar trend was found in CD2+ and CD8+ cells but without statistical significance. Macroscopically healthy proximal untreated samples showed significant decrease in densities of CD2+, CD4+ and CD8+ lymphocytes in casein-treated group when compared with control samples. In casein-treated animals the density of CD45+ cells in the non-injected bowel was also decreased, but this did not reach statistical significance. Densities of CD1+ and IgM+ cells did not differ between casein-treated and saline-treated groups. A significant T-cell decrease was found in the present NEC model. Surprisingly, this was most prominent in the macroscopically healthy bowel outside the casein injection segment. The reason for T-cell decrease remains unclear, but bovine casein is known to contain peptide fractions that can modulate immune function. These findings may have implications in the design of neonatal milk formulas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764628     DOI: 10.1007/s00383-003-1004-7

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  22 in total

Review 1.  Effects of milk-derived bioactives: an overview.

Authors:  N P Shah
Journal:  Br J Nutr       Date:  2000-11       Impact factor: 3.718

2.  Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis.

Authors:  N N Nanthakumar; R D Fusunyan; I Sanderson; W A Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Analysis of monoclonal antibodies reactive with the porcine CD2 antigen.

Authors:  M D Pescovitz; B Aasted; A Canals; J Dominguez; J S Vizcaino; R Pospisil; J Sinkora; H Salmon; I Valpotic; W C Davis
Journal:  Vet Immunol Immunopathol       Date:  1994-10       Impact factor: 2.046

Review 4.  Role of bacterial translocation in necrotizing enterocolitis.

Authors:  E A Deitch
Journal:  Acta Paediatr Suppl       Date:  1994

Review 5.  Neonatal gastrointestinal mucosal immunity.

Authors:  E Mannick; J N Udall
Journal:  Clin Perinatol       Date:  1996-06       Impact factor: 3.430

6.  The epidemiology of necrotizing enterocolitis infant mortality in the United States.

Authors:  R C Holman; B J Stoll; M J Clarke; R I Glass
Journal:  Am J Public Health       Date:  1997-12       Impact factor: 9.308

7.  An intraluminal model of necrotizing enterocolitis in the developing neonatal piglet.

Authors:  M Di Lorenzo; J Bass; A Krantis
Journal:  J Pediatr Surg       Date:  1995-08       Impact factor: 2.545

8.  Analyses of mAb reactive with porcine CD8.

Authors:  A Saalmüller; B Aasted; A Canals; J Dominguez; T Goldman; J K Lunney; S Maurer; M D Pescovitz; R Pospisil; H Salmon
Journal:  Vet Immunol Immunopathol       Date:  1994-10       Impact factor: 2.046

Review 9.  Necrotizing enterocolitis: the search for a unifying pathogenic theory leading to prevention.

Authors:  J Neu
Journal:  Pediatr Clin North Am       Date:  1996-04       Impact factor: 3.278

Review 10.  Epidemiology of necrotizing enterocolitis.

Authors:  B J Stoll
Journal:  Clin Perinatol       Date:  1994-06       Impact factor: 3.430

View more
  6 in total

1.  Necrotising enterocolitis is characterised by disrupted immune regulation and diminished mucosal regulatory (FOXP3)/effector (CD4, CD8) T cell ratios.

Authors:  Jörn-Hendrik Weitkamp; Tatsuki Koyama; Michael T Rock; Hernan Correa; Jeremy A Goettel; Pranathi Matta; Kyra Oswald-Richter; Michael J Rosen; Brian G Engelhardt; Daniel J Moore; D Brent Polk
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

Review 2.  Immunologic and Hematological Abnormalities in Necrotizing Enterocolitis.

Authors:  Akhil Maheshwari
Journal:  Clin Perinatol       Date:  2015-05-13       Impact factor: 3.430

Review 3.  The development of animal models for the study of necrotizing enterocolitis.

Authors:  Chhinder Sodhi; Ward Richardson; Steven Gribar; David J Hackam
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

4.  Mapping the New World of Necrotizing Enterocolitis (NEC): Review and Opinion.

Authors:  Phillip Gordon; Robert Christensen; Jörn-Hendrik Weitkamp; Akhil Maheshwari
Journal:  EJ Neonatol Res       Date:  2012

Review 5.  Precision-based modeling approaches for necrotizing enterocolitis.

Authors:  Mark L Kovler; Chhinder P Sodhi; David J Hackam
Journal:  Dis Model Mech       Date:  2020-06-24       Impact factor: 5.758

6.  Cytokines associated with necrotizing enterocolitis in extremely-low-birth-weight infants.

Authors:  Akhil Maheshwari; Robert L Schelonka; Reed A Dimmitt; Waldemar A Carlo; Breda Munoz-Hernandez; Abhik Das; Scott A McDonald; Poul Thorsen; Kristin Skogstrand; David M Hougaard; Rosemary D Higgins
Journal:  Pediatr Res       Date:  2014-04-14       Impact factor: 3.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.